Rapid growth in injectables driven by pharm de-risking and biological pipeline, outlined in CPhI annual report
Piramal Enterprises’ Pharma Solutions division has delivered its comprehensive review of the injectables market, both sterile and small molecule, for the next five years during its CPhI annual report piece. The review indicates that the near-term growth prospects are highest across generics, small molecule injectables, and in contract services.
Vivek Sharma, Chief Executive Officer, Pharma Solutions, Piramal Enterprises said, “Outsourcing in the sterile injectable segment is still focused on the US, followed by the European Union. We anticipate this market to continue growing at around 10 per cent annually for the next five years, with US remaining the most preferred outsourcing destination.”
Sharma said, “We recently acquired Coldstream in Kentucky, US to enhance our sterile injectables service offering. We expect that over the next few years there will be further acquisitions by both generic and big pharma players as companies look to gain a foothold in the growing sterile injectables space. In particular, we see this access to manufacturing infrastructure as a key driver for future consolidations.”
The US remains the primary outsourcing destination, particularly for high value and biological formulations. However, in the longer term, it is predicted that lower cost firms in India and China may try to enter with generic injectables. Over the next few years, CMOs focused on prefilled syringes and those with high potent handling capabilities are expected to be the biggest beneficiaries of market growth.